ArticleChemical research in toxicology2025
Chemoproteomic Approach for Identifying Nuclear Arsenite-Binding Proteins.
Article in Chemical research in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Trivalent arsenic, i.e., As(III), is the main form of arsenic species in the environment. Prolonged exposure to arsenicals through ingesting contaminated food and water has been implicated in the development of cancer and diabetes as well as cardiovascular and neurodegenerative diseases. A number of studies have been conducted to examine the mechanisms underlying the toxic effects of arsenite exposure, where As(III) was shown to displace Zn(II) and impair the functions of zinc-binding proteins. Considering that many zinc-binding proteins can bind to nucleic acids, we reason that systematic identification of arsenite-binding proteins in the nucleus may provide additional insights into the molecular targets of arsenite, thereby improving our understanding of the mechanisms of arsenic toxicity. Here, we conducted a quantitative proteomics experiment relying on affinity pull-down from nuclear protein lysate with a biotin-As(III) probe to identify nuclear arsenite-binding proteins. We uncovered a number of candidate As(III)-binding proteins that are involved in mRNA splicing, DNA repair, and replication. We also found that As(III) could bind to splicing factor 1 (SF1) and that this binding perturbs mRNA splicing in human cells. Together, our work provided insights into the mechanisms of As(III) toxicity by revealing new nuclear protein targets of As(III).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.